Dublin, July 29, 2022 (GLOBE NEWSWIRE) -- The "Pharmaceutical Drug Delivery Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
The global pharmaceutical drug delivery market reached a value of US$ 1,242.8 Billion in 2021. Looking forward, the publisher expects the market to reach a value of US$ 1,753.9 Billion by 2027, exhibiting a CAGR of 5.91% during 2021-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Pharmaceutical drug delivery is a method of administering therapeutic substances into the body. It improves efficiency, safety, and patient experience by controlling the rate, time, and place of drug release. At present, different types of drug delivery systems are available for the release of various therapeutic agents. For instance, gels, liposomes, microspheres, prodrugs, and cyclodextrins are among the effective systems used for peptide and protein therapeutics.
Pharmaceutical Drug Delivery Market Trends:
The growing prevalence of diseases, such as respiratory, leishmaniasis, central nervous system (CNS), and systemic fungal infections, represents one of the key factors bolstering the market growth. Moreover, a significant increase in the number of death rates among the older population and individuals who have cancer is catalyzing the demand for pharmaceutical drug delivery systems.
These systems provide enhanced efficacy and reduced toxicity for anticancer agents. The market is also influenced by consumer inclination towards personalized and minimally invasive (MI) medical therapy. Apart from this, nanoparticles composed of biodegradable polymers are gaining popularity for enhancing drug delivery to the brain. They also assist in fulfilling the stringent requirements placed on drug delivery systems by governing agencies of numerous countries.
These requirements generally include stability against forces generated during aerosolization, biocompatibility, targeting specific sites or cell populations in the lung, drug release in a predetermined manner, and degradation within an acceptable period. In line with this, researchers are focusing on developing new drug delivery systems, which is contributing to market growth.
Furthermore, with the surging cases of coronavirus disease (COVID-19) across the globe, there is a rise in the demand for pharmaceutical drugs, which, in turn, is anticipated to fuel the market growth.
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Amgen Inc., AstraZeneca plc, Becton Dickinson and Company, Eli Lilly and Company, GSK plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc. and Sanofi S.A.
Key Questions Answered in This Report:
- How has the global pharmaceutical drug delivery market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global pharmaceutical drug delivery market?
- What are the key regional markets?
- What is the breakup of the market based on the route of administration?
- What is the breakup of the market based on the application?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global pharmaceutical drug delivery market and who are the key players?
- What is the degree of competition in the industry?
Key Topics Covered:
1 Preface
2 Scope and Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Pharmaceutical Drug Delivery Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Route of Administration
6.1 Oral Drug Delivery
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Injectable Drug Delivery
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Topical Drug Delivery
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Ocular Drug Delivery
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Pulmonary Drug Delivery
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Implantable Drug Delivery
6.6.1 Market Trends
6.6.2 Market Forecast
6.7 Transmucosal Drug Delivery
6.7.1 Market Trends
6.7.2 Market Forecast
6.8 Nasal Drug Delivery
6.8.1 Market Trends
6.8.2 Market Forecast
7 Market Breakup by Application
7.1 Infectious Diseases
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Cancer
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Cardiovascular Diseases
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Diabetes
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Respiratory Diseases
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Central Nervous System Disorders
7.6.1 Market Trends
7.6.2 Market Forecast
7.7 Autoimmune Diseases
7.7.1 Market Trends
7.7.2 Market Forecast
7.8 Others
7.8.1 Market Trends
7.8.2 Market Forecast
8 Market Breakup by End User
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Ambulatory Surgery Centers
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Home Care Settings
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Diagnostic Centers
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Others
8.5.1 Market Trends
8.5.2 Market Forecast
9 Market Breakup by Region
10 SWOT Analysis
11 Value Chain Analysis
12 Porters Five Forces Analysis
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 AbbVie Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Amgen Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 AstraZeneca plc
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Becton Dickinson and Company
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 Eli Lilly and Company
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 GSK plc
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 Johnson & Johnson
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 Merck KGaA
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 Novartis AG
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.9.4 SWOT Analysis
14.3.10 Pfizer Inc.
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.10.4 SWOT Analysis
14.3.11 Sanofi S.A.
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Financials
For more information about this report visit https://www.researchandmarkets.com/r/leaca1
Attachment
